ArcherDX partners with Illumina on companion tests

2019 04 24 18 42 4242 Dna Blue 400

Diagnostics company ArcherDX is partnering with Illumina to develop its next-generation sequencing companion tests for oncology indications.

Boulder, CO-based ArcherDX is developing a portfolio of IVD tests for assessing targeted therapies based on genetic mutation profiles and monitoring minimal residual disease/treatment response in patients with solid and hematological malignancies.

Per the partnership, ArcherDX will secure approvals for the IVD kits and be in charge of commercialization, and the tests will be usable with Illumina's NextSeq 550Dx analyzer. The companies previously inked a similar deal to pave the way for use of the tests with Illumina's MiSeqDx system.

Page 1 of 1